Cefpodoxime & Potassium Clavulanate Oral Suspension – Tilpod CV Suspension

Tilpod CV Suspension
Composition:- Cefpodoxime 50 mg + Clavulanic Acid 31.25 mg with Water

Tilpod CV Suspension – This Cefpodoxime & Potassium Clavulanate Oral Suspension combines Cefpodoxime, a third-generation cephalosporin, with Clavulanic Acid, a beta-lactamase inhibitor. Cefpodoxime inhibits bacterial cell wall synthesis, while Clavulanic Acid protects it from degradation by beta-lactamase enzymes, thereby extending its antibacterial spectrum. The combination is effective against a wide range of pathogens responsible for common pediatric infections.

Marketed by: Wonne International Pvt. Ltd.

Key Points of Cefpodoxime & Potassium Clavulanate Oral Suspension – Tilpod CV Suspension

• Broad-Spectrum Antibacterial Coverage: Effective against a wide range of gram-positive and gram-negative organisms, including beta-lactamase-producing strains.
• Beta-Lactamase Protection: Clavulanic Acid inhibits bacterial enzymes that cause resistance, enhancing the efficacy of Cefpodoxime.
• Dual Mechanism of Action: Combines bactericidal activity with resistance protection for improved treatment outcomes.
• Effective in Common Pediatric Infections: Widely used in respiratory tract infections, ENT infections, and urinary tract infections in children.
• Palatable Pediatric Formulation: Designed as an oral suspension to improve taste, ease of administration, and compliance in children.

Can be Prescribed by:

• Pediatricians
• General Physicians
• ENT Specialists
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.